[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6D8aLB4N7WQDHIYM6JgSfxgk2Q02sZ2KIUKiYSH0Veg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":62,"rows":69},"Janssen Pharmaceutical K.K.",[4],127,false,5,45,14498,6,2,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Healthy",26,{"name":18,"count":19},"Multiple Myeloma",10,{"name":21,"count":22},"Schizophrenia",9,{"name":24,"count":25},"Pain",7,{"name":27,"count":11},"Hepatitis C, Chronic",{"name":29,"count":30},"Chronic Pain",4,{"name":32,"count":30},"Alzheimer's Disease",{"name":34,"count":35},"Low Back Pain",3,[37,42,47,52,57],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04325828","A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","2021-06-09","Apalutamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06295692","A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","2025-01-14","JNJ-77242113",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05567185","A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","2025-03-11","Erdafitinib Intravesical Delivery System",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04696809","A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma","2026-04-22","Teclistamab",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05926583","A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa","2027-06-30","AAV5-hRKp.RPGR",[63,64,65,66,67,68],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[70,106,127,150,171,205,227,262,285,309,327,350,375,398,474,538,568,616,671,716,764,797,830,852,889,923,953,971,989,1007,1025,1047,1072,1098,1116,1142,1160,1186,1204,1229,1247,1278,1296,1321,1345,1363,1381,1406,1424,1442,1460,1485,1503,1521,1539,1557,1582,1604,1627,1652,1698,1730,1762,1797,1819,1837,1855,1878,1904,1929,1954,1972,1997,2015,2033,2059,2077,2102,2120,2148,2173,2191,2214,2240,2264,2286,2311,2340,2365,2391,2416,2434,2452,2470,2492,2515,2543,2561,2579,2597,2615,2638,2662,2680,2705,2723,2741,2765,2789,2813,2831,2855,2876,2900,2924,2950,2968,2991,3017,3035,3053,3071,3096,3114,3132,3156,3178,3203,3221,3239,3257,3281,3305,3329,3347,3365,3386,3409,3432,3455,3478,3501,3519,3543,3561,3584,3606,3629,3647,3673,3709,3727,3745,3763,3781],{"intervention":46,"totalTrials":12,"cells":71},{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":87,"PHASE3":89,"PHASE4":102,"NA":104},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[77],{"nctId":78,"briefTitle":79,"status":80,"phases":81,"primaryCompletion":82,"completion":82,"start":83,"enrollment":84,"conditions":85,"interventions":86},"NCT05062200","A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants","COMPLETED",[64],"2022-09-28","2021-10-25",36,[15],[46],{"trials":88,"activeCount":74},[],{"trials":90,"activeCount":101,"soonestReadout":45},[91],{"nctId":43,"briefTitle":44,"status":92,"phases":93,"primaryCompletion":45,"completion":94,"start":95,"enrollment":96,"conditions":97,"interventions":100},"ACTIVE_NOT_RECRUITING",[66],"2027-10-14","2024-02-09",19,[98,99],"Generalized Pustular Psoriasis","Erythrodermic Psoriasis",[46],1,{"trials":103,"activeCount":74},[],{"trials":105,"activeCount":74},[],{"intervention":61,"totalTrials":101,"cells":107},{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":123,"NA":125},{"trials":109,"activeCount":74},[],{"trials":111,"activeCount":74},[],{"trials":113,"activeCount":74},[],{"trials":115,"activeCount":101,"soonestReadout":60},[116],{"nctId":58,"briefTitle":59,"status":92,"phases":117,"primaryCompletion":60,"completion":118,"start":119,"enrollment":30,"conditions":120,"interventions":122},[66],"2030-11-12","2023-09-12",[121],"Retinitis Pigmentosa",[61,61],{"trials":124,"activeCount":74},[],{"trials":126,"activeCount":74},[],{"intervention":128,"totalTrials":101,"cells":129},"GnRH Agonist",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":131,"activeCount":74},[],{"trials":133,"activeCount":74},[],{"trials":135,"activeCount":101,"soonestReadout":40},[136],{"nctId":38,"briefTitle":39,"status":92,"phases":137,"primaryCompletion":40,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},[65],"2027-12-31","2020-04-07",31,[142],"Salivary Gland Neoplasms",[41,128],{"trials":145,"activeCount":74},[],{"trials":147,"activeCount":74},[],{"trials":149,"activeCount":74},[],{"intervention":56,"totalTrials":101,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":153,"activeCount":74},[],{"trials":155,"activeCount":74},[],{"trials":157,"activeCount":101,"soonestReadout":55},[158],{"nctId":53,"briefTitle":54,"status":92,"phases":159,"primaryCompletion":55,"completion":55,"start":160,"enrollment":161,"conditions":162,"interventions":164},[64,65],"2021-02-22",40,[163],"Hematologic Malignancies",[56],{"trials":166,"activeCount":74},[],{"trials":168,"activeCount":74},[],{"trials":170,"activeCount":74},[],{"intervention":41,"totalTrials":12,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":174,"activeCount":74},[],{"trials":176,"activeCount":74},[],{"trials":178,"activeCount":101,"soonestReadout":40},[179],{"nctId":38,"briefTitle":39,"status":92,"phases":180,"primaryCompletion":40,"completion":138,"start":139,"enrollment":140,"conditions":181,"interventions":182},[65],[142],[41,128],{"trials":184,"activeCount":74},[],{"trials":186,"activeCount":74},[],{"trials":188,"activeCount":74},[189],{"nctId":190,"briefTitle":191,"status":80,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT04034095","A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan",[],"2024-08-13","2019-07-08",979,[197],"Prostatic Neoplasms",[199,200,201,202,203,204,41],"Androgen-deprivation Therapy","Bicalutamide","Abiraterone","Prednisolone","Docetaxel","Enzalutamide",{"intervention":51,"totalTrials":101,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":208,"activeCount":74},[],{"trials":210,"activeCount":101,"soonestReadout":50},[211],{"nctId":48,"briefTitle":49,"status":92,"phases":212,"primaryCompletion":50,"completion":213,"start":214,"enrollment":8,"conditions":215,"interventions":218},[64],"2026-08-30","2023-03-03",[216,217],"Urinary Bladder Neoplasms","Receptors, Fibroblast Growth Factor",[51],{"trials":220,"activeCount":74},[],{"trials":222,"activeCount":74},[],{"trials":224,"activeCount":74},[],{"trials":226,"activeCount":74},[],{"intervention":228,"totalTrials":12,"cells":229},"Galantamine",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":249,"NA":260},{"trials":231,"activeCount":74},[],{"trials":233,"activeCount":74},[],{"trials":235,"activeCount":74},[],{"trials":237,"activeCount":74},[238],{"nctId":239,"briefTitle":240,"status":80,"phases":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT00301574","An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.",[66],"2004-02","2001-04",398,[246],"Alzheimer Disease",[248],"galantamine",{"trials":250,"activeCount":74},[251],{"nctId":252,"briefTitle":253,"status":80,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":259},"NCT01478633","Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil",[67],"2013-06","2011-09",102,[32],[228],{"trials":261,"activeCount":74},[],{"intervention":263,"totalTrials":101,"cells":264},"TMC278",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":283},{"trials":266,"activeCount":74},[],{"trials":268,"activeCount":74},[],{"trials":270,"activeCount":74},[],{"trials":272,"activeCount":74},[],{"trials":274,"activeCount":74},[275],{"nctId":276,"briefTitle":277,"status":80,"phases":278,"primaryCompletion":279,"completion":279,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT01804244","A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants",[67],"2013-03",8,[15],[263],{"trials":284,"activeCount":74},[],{"intervention":286,"totalTrials":101,"cells":287},"Darunavir",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":307},{"trials":289,"activeCount":74},[],{"trials":291,"activeCount":74},[],{"trials":293,"activeCount":74},[],{"trials":295,"activeCount":74},[],{"trials":297,"activeCount":74},[298],{"nctId":299,"briefTitle":300,"status":80,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":280,"conditions":304,"interventions":305},"NCT01810887","A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants",[67],"2008-07","2008-05",[15],[286,306],"Ritonavir",{"trials":308,"activeCount":74},[],{"intervention":306,"totalTrials":101,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":325},{"trials":312,"activeCount":74},[],{"trials":314,"activeCount":74},[],{"trials":316,"activeCount":74},[],{"trials":318,"activeCount":74},[],{"trials":320,"activeCount":74},[321],{"nctId":299,"briefTitle":300,"status":80,"phases":322,"primaryCompletion":302,"completion":302,"start":303,"enrollment":280,"conditions":323,"interventions":324},[67],[15],[286,306],{"trials":326,"activeCount":74},[],{"intervention":328,"totalTrials":101,"cells":329},"Rilpivirine\u002FTenofovir Disoproxil Fumarate\u002FEmtricitabine FDC",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":348},{"trials":331,"activeCount":74},[],{"trials":333,"activeCount":74},[],{"trials":335,"activeCount":74},[],{"trials":337,"activeCount":74},[],{"trials":339,"activeCount":74},[340],{"nctId":341,"briefTitle":342,"status":80,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":280,"conditions":346,"interventions":347},"NCT02530060","A Study to Evaluate the Pharmacokinetics of Rilpivirine\u002FTenofovir\u002FEmtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants",[67],"2015-09","2015-08",[15],[328],{"trials":349,"activeCount":74},[],{"intervention":351,"totalTrials":101,"cells":352},"Abiraterone Acetate",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":373},{"trials":354,"activeCount":74},[],{"trials":356,"activeCount":74},[],{"trials":358,"activeCount":74},[],{"trials":360,"activeCount":74},[],{"trials":362,"activeCount":74},[363],{"nctId":364,"briefTitle":365,"status":80,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT02405858","A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy",[67],"2017-12-31","2015-04-10",51,[371],"Metastatic Castration-Resistant Prostate Cancer",[351,202],{"trials":374,"activeCount":74},[],{"intervention":376,"totalTrials":101,"cells":377},"Darunavir\u002FCobicistat",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":396},{"trials":379,"activeCount":74},[],{"trials":381,"activeCount":74},[],{"trials":383,"activeCount":74},[],{"trials":385,"activeCount":74},[],{"trials":387,"activeCount":74},[388],{"nctId":389,"briefTitle":390,"status":80,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":280,"conditions":394,"interventions":395},"NCT03123848","A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir\u002FCobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants",[67],"2017-05-19","2017-04-14",[15],[376],{"trials":397,"activeCount":74},[],{"intervention":399,"totalTrials":11,"cells":400},"Fentanyl",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":418,"PHASE4":470,"NA":472},{"trials":402,"activeCount":74},[],{"trials":404,"activeCount":74},[],{"trials":406,"activeCount":74},[407],{"nctId":408,"briefTitle":409,"status":80,"phases":410,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":416},"NCT00216658","Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -",[65],"2005-09","2004-12",87,[415],"Pain, Intractable",[417],"fentanyl",{"trials":419,"activeCount":74},[420,429,441,451,461],{"nctId":421,"briefTitle":422,"status":80,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT00788372","An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain",[66],"2010-11","2008-11",142,[29],[399],{"nctId":430,"briefTitle":431,"status":80,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":440},"NCT01008553","A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome",[66],"2010-03","2008-12",258,[437,438,439],"Postherpetic Neuralgia","Complex Regional Pain Syndromes (CRPS)","Postoperative Pain",[399],{"nctId":442,"briefTitle":443,"status":80,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT01008618","A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain",[66],"2010-02","2009-01",218,[29,449,34],"Osteoarthritis",[399],{"nctId":452,"briefTitle":453,"status":80,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT00641667","An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain",[66],"2008-06","2008-01",66,[24,459],"Cancer",[399],{"nctId":462,"briefTitle":463,"status":80,"phases":464,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":469},"NCT00216684","Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics",[66],"2006-09","2005-05",139,[415],[417],{"trials":471,"activeCount":74},[],{"trials":473,"activeCount":74},[],{"intervention":475,"totalTrials":8,"cells":476},"TMC435",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":494,"PHASE4":534,"NA":536},{"trials":478,"activeCount":74},[],{"trials":480,"activeCount":74},[],{"trials":482,"activeCount":74},[483],{"nctId":484,"briefTitle":485,"status":80,"phases":486,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":491},"NCT00996476","A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients",[65],"2011-01","2009-07",92,[27],[475,492,493],"PegIFNα-2a","RBV",{"trials":495,"activeCount":74},[496,506,516,526],{"nctId":497,"briefTitle":498,"status":80,"phases":499,"primaryCompletion":500,"completion":500,"start":487,"enrollment":501,"conditions":502,"interventions":503},"NCT01290731","A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy",[66],"2012-08",49,[27],[475,504,505],"Pegylated interferon","Ribavirin",{"nctId":507,"briefTitle":508,"status":80,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":514},"NCT01288209","A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy",[66],"2012-09","2011-02",106,[27],[475,515,505],"Peginterferon alfa-2a",{"nctId":517,"briefTitle":518,"status":80,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":524},"NCT01366638","A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection",[66],"2012-11","2011-05",79,[27],[475,525,505],"Peginterferon alfa-2b",{"nctId":527,"briefTitle":528,"status":80,"phases":529,"primaryCompletion":530,"completion":530,"start":511,"enrollment":531,"conditions":532,"interventions":533},"NCT01292239","A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients",[66],"2012-10",183,[27],[475,515,505],{"trials":535,"activeCount":74},[],{"trials":537,"activeCount":74},[],{"intervention":505,"totalTrials":30,"cells":539},{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":564,"NA":566},{"trials":541,"activeCount":74},[],{"trials":543,"activeCount":74},[],{"trials":545,"activeCount":74},[],{"trials":547,"activeCount":74},[548,552,556,560],{"nctId":497,"briefTitle":498,"status":80,"phases":549,"primaryCompletion":500,"completion":500,"start":487,"enrollment":501,"conditions":550,"interventions":551},[66],[27],[475,504,505],{"nctId":507,"briefTitle":508,"status":80,"phases":553,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":554,"interventions":555},[66],[27],[475,515,505],{"nctId":517,"briefTitle":518,"status":80,"phases":557,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":558,"interventions":559},[66],[27],[475,525,505],{"nctId":527,"briefTitle":528,"status":80,"phases":561,"primaryCompletion":530,"completion":530,"start":511,"enrollment":531,"conditions":562,"interventions":563},[66],[27],[475,515,505],{"trials":565,"activeCount":74},[],{"trials":567,"activeCount":74},[],{"intervention":569,"totalTrials":30,"cells":570},"Paliperidone palmitate",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":583,"PHASE3":594,"PHASE4":612,"NA":614},{"trials":572,"activeCount":74},[],{"trials":574,"activeCount":74},[575],{"nctId":576,"briefTitle":577,"status":80,"phases":578,"primaryCompletion":433,"completion":433,"start":579,"enrollment":580,"conditions":581,"interventions":582},"NCT01942382","A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia",[64],"2009-04",76,[21],[569],{"trials":584,"activeCount":74},[585],{"nctId":586,"briefTitle":587,"status":80,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT01606254","A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia",[65],"2008-04","2007-01",56,[21],[569],{"trials":595,"activeCount":74},[596,605],{"nctId":597,"briefTitle":598,"status":80,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":604},"NCT01299389","An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia",[66],"2012-05","2010-10",323,[21],[569],{"nctId":606,"briefTitle":607,"status":80,"phases":608,"primaryCompletion":520,"completion":520,"start":601,"enrollment":609,"conditions":610,"interventions":611},"NCT01258920","A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia",[66],201,[21],[569],{"trials":613,"activeCount":74},[],{"trials":615,"activeCount":74},[],{"intervention":617,"totalTrials":30,"cells":618},"Ibrutinib",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":632,"PHASE3":656,"PHASE4":667,"NA":669},{"trials":620,"activeCount":74},[],{"trials":622,"activeCount":74},[623],{"nctId":624,"briefTitle":625,"status":80,"phases":626,"primaryCompletion":627,"completion":627,"start":628,"enrollment":280,"conditions":629,"interventions":631},"NCT02556892","A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[64],"2018-08-20","2015-07-03",[630],"Lymphocytic Leukemia",[617],{"trials":633,"activeCount":74},[634,646],{"nctId":635,"briefTitle":636,"status":80,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT04062448","A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)",[65],"2021-08-24","2023-03-02","2019-09-25",16,[643],"Waldenstrom Macroglobulinemia",[617,645],"Rituximab",{"nctId":647,"briefTitle":648,"status":80,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":641,"conditions":653,"interventions":655},"NCT02169180","Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma",[65],"2016-11","2016-12","2014-08",[654],"Lymphoma, Mantle-cell",[617],{"trials":657,"activeCount":74},[658],{"nctId":659,"briefTitle":660,"status":80,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":96,"conditions":664,"interventions":666},"NCT03474679","A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent\u002FRefractory Chronic Graft Versus Host Disease (cGVHD)",[66],"2021-11-29","2018-05-01",[665],"Graft vs Host Disease",[617],{"trials":668,"activeCount":74},[],{"trials":670,"activeCount":74},[],{"intervention":672,"totalTrials":35,"cells":673},"risperidone",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":712,"NA":714},{"trials":675,"activeCount":74},[],{"trials":677,"activeCount":74},[],{"trials":679,"activeCount":74},[],{"trials":681,"activeCount":74},[682,693,703],{"nctId":683,"briefTitle":684,"status":685,"phases":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT00287742","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease","TERMINATED",[66],"2003-03","2002-03",33,[32,691],"Dementia",[672],{"nctId":694,"briefTitle":695,"status":80,"phases":696,"primaryCompletion":697,"completion":697,"start":510,"enrollment":698,"conditions":699,"interventions":701},"NCT01624675","A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder",[66],"2014-10",39,[700],"Autistic Disorder in Children and Adolescents",[702],"Risperidone",{"nctId":704,"briefTitle":705,"status":80,"phases":706,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT00240708","A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia",[66],"2006-04","2004-06",205,[21],[672],{"trials":713,"activeCount":74},[],{"trials":715,"activeCount":74},[],{"intervention":717,"totalTrials":35,"cells":718},"Guselkumab",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":760,"NA":762},{"trials":720,"activeCount":74},[],{"trials":722,"activeCount":74},[],{"trials":724,"activeCount":74},[],{"trials":726,"activeCount":74},[727,738,749],{"nctId":728,"briefTitle":729,"status":80,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":737},"NCT04397263","A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease",[66],"2024-02-29","2025-09-12","2020-06-10",38,[736],"Crohns Disease",[717],{"nctId":739,"briefTitle":740,"status":80,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT02641730","An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis",[66],"2017-03-28","2018-07-17","2015-12-15",159,[747],"Palmoplantar Pustulosis",[717],{"nctId":750,"briefTitle":751,"status":80,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT02343744","An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis",[66],"2015-12-04","2018-11-02","2015-01-19",21,[758],"Pustular Psoriasis",[717],{"trials":761,"activeCount":74},[],{"trials":763,"activeCount":74},[],{"intervention":765,"totalTrials":12,"cells":766},"JNS001",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":793,"NA":795},{"trials":768,"activeCount":74},[],{"trials":770,"activeCount":74},[],{"trials":772,"activeCount":74},[],{"trials":774,"activeCount":74},[775,783],{"nctId":776,"briefTitle":777,"status":80,"phases":778,"primaryCompletion":279,"completion":279,"start":521,"enrollment":779,"conditions":780,"interventions":782},"NCT01357993","A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder",[66],253,[781],"Attention-Deficit \u002F Hyperactivity Disorder",[765],{"nctId":784,"briefTitle":785,"status":80,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":790,"interventions":792},"NCT01323192","An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder",[66],"2012-04","2011-03",284,[791],"Attention-Deficit Hyperactivity Disorder",[765],{"trials":794,"activeCount":74},[],{"trials":796,"activeCount":74},[],{"intervention":798,"totalTrials":12,"cells":799},"CNTO 148",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":826,"NA":828},{"trials":801,"activeCount":74},[],{"trials":803,"activeCount":74},[],{"trials":805,"activeCount":74},[],{"trials":807,"activeCount":74},[808,817],{"nctId":809,"briefTitle":810,"status":80,"phases":811,"primaryCompletion":812,"completion":812,"start":303,"enrollment":813,"conditions":814,"interventions":816},"NCT00771251","A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)",[66],"2011-10",311,[815],"Rheumatoid Arthritis",[798],{"nctId":818,"briefTitle":819,"status":80,"phases":820,"primaryCompletion":821,"completion":821,"start":303,"enrollment":822,"conditions":823,"interventions":824},"NCT00727987","A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[66],"2011-12",269,[815],[798,825],"Methotrexate",{"trials":827,"activeCount":74},[],{"trials":829,"activeCount":74},[],{"intervention":515,"totalTrials":12,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":848,"NA":850},{"trials":833,"activeCount":74},[],{"trials":835,"activeCount":74},[],{"trials":837,"activeCount":74},[],{"trials":839,"activeCount":74},[840,844],{"nctId":507,"briefTitle":508,"status":80,"phases":841,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":842,"interventions":843},[66],[27],[475,515,505],{"nctId":527,"briefTitle":528,"status":80,"phases":845,"primaryCompletion":530,"completion":530,"start":511,"enrollment":531,"conditions":846,"interventions":847},[66],[27],[475,515,505],{"trials":849,"activeCount":74},[],{"trials":851,"activeCount":74},[],{"intervention":853,"totalTrials":12,"cells":854},"Ustekinumab 90 mg",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":885,"NA":887},{"trials":856,"activeCount":74},[],{"trials":858,"activeCount":74},[],{"trials":860,"activeCount":74},[],{"trials":862,"activeCount":74},[863,875],{"nctId":864,"briefTitle":865,"status":685,"phases":866,"primaryCompletion":867,"completion":868,"start":869,"enrollment":369,"conditions":870,"interventions":873},"NCT03981744","A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments",[66],"2022-01-24","2022-07-12","2019-07-26",[871,872],"Polymyositis","Dermatomyositis",[874,853],"Ustekinumab 6 mg\u002Fkg",{"nctId":876,"briefTitle":877,"status":80,"phases":878,"primaryCompletion":446,"completion":433,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT00723528","An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis",[66],"2008-03",158,[882],"Psoriasis",[884,853,884,853],"Ustekinumab 45 mg",{"trials":886,"activeCount":74},[],{"trials":888,"activeCount":74},[],{"intervention":890,"totalTrials":12,"cells":891},"Tramadol Hydrochloride",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":919,"NA":921},{"trials":893,"activeCount":74},[],{"trials":895,"activeCount":74},[],{"trials":897,"activeCount":74},[],{"trials":899,"activeCount":74},[900,910],{"nctId":901,"briefTitle":902,"status":80,"phases":903,"primaryCompletion":904,"completion":904,"start":879,"enrollment":905,"conditions":906,"interventions":907},"NCT00737048","A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain",[66],"2008-09",328,[24,439],[890,908,909],"Acetaminophen","Tramadol plus Acetaminophen",{"nctId":911,"briefTitle":912,"status":80,"phases":913,"primaryCompletion":914,"completion":915,"start":303,"enrollment":916,"conditions":917,"interventions":918},"NCT00736957","A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain",[66],"2009-10","2009-11",219,[29],[890],{"trials":920,"activeCount":74},[],{"trials":922,"activeCount":74},[],{"intervention":924,"totalTrials":101,"cells":925},"Bedaquiline",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":949,"NA":951},{"trials":927,"activeCount":74},[],{"trials":929,"activeCount":74},[],{"trials":931,"activeCount":74},[],{"trials":933,"activeCount":74},[934],{"nctId":935,"briefTitle":936,"status":80,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":944},"NCT04630145","A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)",[65,66],"2024-11-06","2025-11-14","2021-01-08",129,[943],"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)",[924,945,946,947,948],"Clarithromycin","Ethambutol","Rifampicin","Rifabutin",{"trials":950,"activeCount":74},[],{"trials":952,"activeCount":74},[],{"intervention":945,"totalTrials":101,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":967,"NA":969},{"trials":956,"activeCount":74},[],{"trials":958,"activeCount":74},[],{"trials":960,"activeCount":74},[],{"trials":962,"activeCount":74},[963],{"nctId":935,"briefTitle":936,"status":80,"phases":964,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":965,"interventions":966},[65,66],[943],[924,945,946,947,948],{"trials":968,"activeCount":74},[],{"trials":970,"activeCount":74},[],{"intervention":946,"totalTrials":101,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":985,"NA":987},{"trials":974,"activeCount":74},[],{"trials":976,"activeCount":74},[],{"trials":978,"activeCount":74},[],{"trials":980,"activeCount":74},[981],{"nctId":935,"briefTitle":936,"status":80,"phases":982,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":983,"interventions":984},[65,66],[943],[924,945,946,947,948],{"trials":986,"activeCount":74},[],{"trials":988,"activeCount":74},[],{"intervention":947,"totalTrials":101,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":1003,"NA":1005},{"trials":992,"activeCount":74},[],{"trials":994,"activeCount":74},[],{"trials":996,"activeCount":74},[],{"trials":998,"activeCount":74},[999],{"nctId":935,"briefTitle":936,"status":80,"phases":1000,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":1001,"interventions":1002},[65,66],[943],[924,945,946,947,948],{"trials":1004,"activeCount":74},[],{"trials":1006,"activeCount":74},[],{"intervention":948,"totalTrials":101,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1021,"NA":1023},{"trials":1010,"activeCount":74},[],{"trials":1012,"activeCount":74},[],{"trials":1014,"activeCount":74},[],{"trials":1016,"activeCount":74},[1017],{"nctId":935,"briefTitle":936,"status":80,"phases":1018,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":1019,"interventions":1020},[65,66],[943],[924,945,946,947,948],{"trials":1022,"activeCount":74},[],{"trials":1024,"activeCount":74},[],{"intervention":1026,"totalTrials":101,"cells":1027},"JNS020QD",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1043,"NA":1045},{"trials":1029,"activeCount":74},[],{"trials":1031,"activeCount":74},[],{"trials":1033,"activeCount":74},[],{"trials":1035,"activeCount":74},[1036],{"nctId":1037,"briefTitle":1038,"status":80,"phases":1039,"primaryCompletion":279,"completion":279,"start":812,"enrollment":1040,"conditions":1041,"interventions":1042},"NCT01493245","A Study of JNS020QD in Patients With Chronic Pain",[66],77,[29],[1026],{"trials":1044,"activeCount":74},[],{"trials":1046,"activeCount":74},[],{"intervention":1048,"totalTrials":101,"cells":1049},"Macitentan",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1068,"NA":1070},{"trials":1051,"activeCount":74},[],{"trials":1053,"activeCount":74},[],{"trials":1055,"activeCount":74},[],{"trials":1057,"activeCount":74},[1058],{"nctId":1059,"briefTitle":1060,"status":80,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":25,"conditions":1065,"interventions":1067},"NCT05167825","A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension",[66],"2024-08-23","2025-03-05","2022-11-14",[1066],"Pulmonary Arterial Hypertension",[1048],{"trials":1069,"activeCount":74},[],{"trials":1071,"activeCount":74},[],{"intervention":1073,"totalTrials":101,"cells":1074},"Glucorticoid Taper Regimen",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1094,"NA":1096},{"trials":1076,"activeCount":74},[],{"trials":1078,"activeCount":74},[],{"trials":1080,"activeCount":74},[],{"trials":1082,"activeCount":74},[1083],{"nctId":1084,"briefTitle":1085,"status":685,"phases":1086,"primaryCompletion":1087,"completion":1087,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT04882072","A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)",[66],"2023-05-25","2021-09-15",14,[1091],"Takayasu Arteritis",[1093,1073],"Ustekinumab",{"trials":1095,"activeCount":74},[],{"trials":1097,"activeCount":74},[],{"intervention":504,"totalTrials":101,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":74},[],{"trials":1103,"activeCount":74},[],{"trials":1105,"activeCount":74},[],{"trials":1107,"activeCount":74},[1108],{"nctId":497,"briefTitle":498,"status":80,"phases":1109,"primaryCompletion":500,"completion":500,"start":487,"enrollment":501,"conditions":1110,"interventions":1111},[66],[27],[475,504,505],{"trials":1113,"activeCount":74},[],{"trials":1115,"activeCount":74},[],{"intervention":1117,"totalTrials":101,"cells":1118},"CNTO 1959 50 mg",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1138,"NA":1140},{"trials":1120,"activeCount":74},[],{"trials":1122,"activeCount":74},[],{"trials":1124,"activeCount":74},[],{"trials":1126,"activeCount":74},[1127],{"nctId":1128,"briefTitle":1129,"status":80,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT02325219","An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis",[66],"2016-03-02","2019-02-08","2014-12-19",192,[882],[1117,1137],"CTNO 1959 100 mg",{"trials":1139,"activeCount":74},[],{"trials":1141,"activeCount":74},[],{"intervention":1137,"totalTrials":101,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1156,"NA":1158},{"trials":1145,"activeCount":74},[],{"trials":1147,"activeCount":74},[],{"trials":1149,"activeCount":74},[],{"trials":1151,"activeCount":74},[1152],{"nctId":1128,"briefTitle":1129,"status":80,"phases":1153,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1154,"interventions":1155},[66],[882],[1117,1137],{"trials":1157,"activeCount":74},[],{"trials":1159,"activeCount":74},[],{"intervention":1161,"totalTrials":101,"cells":1162},"Tapentadol ER",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1182,"NA":1184},{"trials":1164,"activeCount":74},[],{"trials":1166,"activeCount":74},[],{"trials":1168,"activeCount":74},[],{"trials":1170,"activeCount":74},[1171],{"nctId":1172,"briefTitle":1173,"status":80,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT01309386","A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants",[66],"2012-01","2010-08",100,[1179],"Neoplasms",[1161,1181],"Morphine SR",{"trials":1183,"activeCount":74},[],{"trials":1185,"activeCount":74},[],{"intervention":1181,"totalTrials":101,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":74},[],{"trials":1191,"activeCount":74},[],{"trials":1193,"activeCount":74},[],{"trials":1195,"activeCount":74},[1196],{"nctId":1172,"briefTitle":1173,"status":80,"phases":1197,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1198,"interventions":1199},[66],[1179],[1161,1181],{"trials":1201,"activeCount":74},[],{"trials":1203,"activeCount":74},[],{"intervention":1205,"totalTrials":101,"cells":1206},"Fentanyl 1-day transdermal patch",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1225,"NA":1227},{"trials":1208,"activeCount":74},[],{"trials":1210,"activeCount":74},[],{"trials":1212,"activeCount":74},[],{"trials":1214,"activeCount":74},[1215],{"nctId":1216,"briefTitle":1217,"status":80,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1223},"NCT00644787","A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain",[65,66],"2008-10","2007-12",156,[24,459],[1205,1205,1224],"Fentanyl 3-day transdermal patch",{"trials":1226,"activeCount":74},[],{"trials":1228,"activeCount":74},[],{"intervention":1224,"totalTrials":101,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1243,"NA":1245},{"trials":1232,"activeCount":74},[],{"trials":1234,"activeCount":74},[],{"trials":1236,"activeCount":74},[],{"trials":1238,"activeCount":74},[1239],{"nctId":1216,"briefTitle":1217,"status":80,"phases":1240,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1241,"interventions":1242},[65,66],[24,459],[1205,1205,1224],{"trials":1244,"activeCount":74},[],{"trials":1246,"activeCount":74},[],{"intervention":1248,"totalTrials":101,"cells":1249},"ITCZ Oral Solution",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1274,"NA":1276},{"trials":1251,"activeCount":74},[],{"trials":1253,"activeCount":74},[],{"trials":1255,"activeCount":74},[],{"trials":1257,"activeCount":74},[1258],{"nctId":1259,"briefTitle":1260,"status":80,"phases":1261,"primaryCompletion":579,"completion":1262,"start":456,"enrollment":1263,"conditions":1264,"interventions":1272},"NCT00784368","A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection",[66],"2009-05",55,[1265,1266,1267,1268,1269,1270,1271],"Mycoses","Candidiasis","Aspergillosis","Cryptococcosis","Blastomycosis","Histoplasmosis","Neutropenia",[1248,1273],"ITCZ-IV",{"trials":1275,"activeCount":74},[],{"trials":1277,"activeCount":74},[],{"intervention":1273,"totalTrials":101,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":74},[],{"trials":1283,"activeCount":74},[],{"trials":1285,"activeCount":74},[],{"trials":1287,"activeCount":74},[1288],{"nctId":1259,"briefTitle":1260,"status":80,"phases":1289,"primaryCompletion":579,"completion":1262,"start":456,"enrollment":1263,"conditions":1290,"interventions":1291},[66],[1265,1266,1267,1268,1269,1270,1271],[1248,1273],{"trials":1293,"activeCount":74},[],{"trials":1295,"activeCount":74},[],{"intervention":1297,"totalTrials":101,"cells":1298},"Ad26\u002Fprotein preF RSV Vaccine",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1317,"NA":1319},{"trials":1300,"activeCount":74},[],{"trials":1302,"activeCount":74},[],{"trials":1304,"activeCount":74},[],{"trials":1306,"activeCount":74},[1307],{"nctId":1308,"briefTitle":1309,"status":685,"phases":1310,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT05242432","A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants",[66],"2023-03-20","2022-04-01",2192,[1315],"Respiratory Syncytial Virus Prevention",[1297],{"trials":1318,"activeCount":74},[],{"trials":1320,"activeCount":74},[],{"intervention":1322,"totalTrials":101,"cells":1323},"Galantamine 16 mg\u002Fday",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1341,"NA":1343},{"trials":1325,"activeCount":74},[],{"trials":1327,"activeCount":74},[],{"trials":1329,"activeCount":74},[],{"trials":1331,"activeCount":74},[1332],{"nctId":1333,"briefTitle":1334,"status":80,"phases":1335,"primaryCompletion":904,"completion":904,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT00814801","An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease",[66],"2007-02",580,[32],[1322,1340],"Galantamine 24 mg\u002Fday",{"trials":1342,"activeCount":74},[],{"trials":1344,"activeCount":74},[],{"intervention":1340,"totalTrials":101,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1359,"NA":1361},{"trials":1348,"activeCount":74},[],{"trials":1350,"activeCount":74},[],{"trials":1352,"activeCount":74},[],{"trials":1354,"activeCount":74},[1355],{"nctId":1333,"briefTitle":1334,"status":80,"phases":1356,"primaryCompletion":904,"completion":904,"start":1336,"enrollment":1337,"conditions":1357,"interventions":1358},[66],[32],[1322,1340],{"trials":1360,"activeCount":74},[],{"trials":1362,"activeCount":74},[],{"intervention":825,"totalTrials":101,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1377,"NA":1379},{"trials":1366,"activeCount":74},[],{"trials":1368,"activeCount":74},[],{"trials":1370,"activeCount":74},[],{"trials":1372,"activeCount":74},[1373],{"nctId":818,"briefTitle":819,"status":80,"phases":1374,"primaryCompletion":821,"completion":821,"start":303,"enrollment":822,"conditions":1375,"interventions":1376},[66],[815],[798,825],{"trials":1378,"activeCount":74},[],{"trials":1380,"activeCount":74},[],{"intervention":1382,"totalTrials":101,"cells":1383},"Sirukumab 100 mg",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1402,"NA":1404},{"trials":1385,"activeCount":74},[],{"trials":1387,"activeCount":74},[],{"trials":1389,"activeCount":74},[],{"trials":1391,"activeCount":74},[1392],{"nctId":1393,"briefTitle":1394,"status":80,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":520,"enrollment":1397,"conditions":1398,"interventions":1400},"NCT01689532","A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine",[66],"2015-03",122,[1399],"Arthritis, Rheumatoid",[1382,1401],"Sirukumab 50 mg",{"trials":1403,"activeCount":74},[],{"trials":1405,"activeCount":74},[],{"intervention":1401,"totalTrials":101,"cells":1407},{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1420,"NA":1422},{"trials":1409,"activeCount":74},[],{"trials":1411,"activeCount":74},[],{"trials":1413,"activeCount":74},[],{"trials":1415,"activeCount":74},[1416],{"nctId":1393,"briefTitle":1394,"status":80,"phases":1417,"primaryCompletion":1396,"completion":1396,"start":520,"enrollment":1397,"conditions":1418,"interventions":1419},[66],[1399],[1382,1401],{"trials":1421,"activeCount":74},[],{"trials":1423,"activeCount":74},[],{"intervention":525,"totalTrials":101,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1438,"NA":1440},{"trials":1427,"activeCount":74},[],{"trials":1429,"activeCount":74},[],{"trials":1431,"activeCount":74},[],{"trials":1433,"activeCount":74},[1434],{"nctId":517,"briefTitle":518,"status":80,"phases":1435,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":1436,"interventions":1437},[66],[27],[475,525,505],{"trials":1439,"activeCount":74},[],{"trials":1441,"activeCount":74},[],{"intervention":874,"totalTrials":101,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1456,"NA":1458},{"trials":1445,"activeCount":74},[],{"trials":1447,"activeCount":74},[],{"trials":1449,"activeCount":74},[],{"trials":1451,"activeCount":74},[1452],{"nctId":864,"briefTitle":865,"status":685,"phases":1453,"primaryCompletion":867,"completion":868,"start":869,"enrollment":369,"conditions":1454,"interventions":1455},[66],[871,872],[874,853],{"trials":1457,"activeCount":74},[],{"trials":1459,"activeCount":74},[],{"intervention":1461,"totalTrials":101,"cells":1462},"ER OROS paliperidone",{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1481,"NA":1483},{"trials":1464,"activeCount":74},[],{"trials":1466,"activeCount":74},[],{"trials":1468,"activeCount":74},[],{"trials":1470,"activeCount":74},[1471],{"nctId":1472,"briefTitle":1473,"status":80,"phases":1474,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1479},"NCT00396565","A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia",[66],"2007-11","2006-07",394,[21],[1461,1480],"Olanzapine",{"trials":1482,"activeCount":74},[],{"trials":1484,"activeCount":74},[],{"intervention":1480,"totalTrials":101,"cells":1486},{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1493,"PHASE4":1499,"NA":1501},{"trials":1488,"activeCount":74},[],{"trials":1490,"activeCount":74},[],{"trials":1492,"activeCount":74},[],{"trials":1494,"activeCount":74},[1495],{"nctId":1472,"briefTitle":1473,"status":80,"phases":1496,"primaryCompletion":1475,"completion":1475,"start":1476,"enrollment":1477,"conditions":1497,"interventions":1498},[66],[21],[1461,1480],{"trials":1500,"activeCount":74},[],{"trials":1502,"activeCount":74},[],{"intervention":884,"totalTrials":101,"cells":1504},{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1517,"NA":1519},{"trials":1506,"activeCount":74},[],{"trials":1508,"activeCount":74},[],{"trials":1510,"activeCount":74},[],{"trials":1512,"activeCount":74},[1513],{"nctId":876,"briefTitle":877,"status":80,"phases":1514,"primaryCompletion":446,"completion":433,"start":879,"enrollment":880,"conditions":1515,"interventions":1516},[66],[882],[884,853,884,853],{"trials":1518,"activeCount":74},[],{"trials":1520,"activeCount":74},[],{"intervention":908,"totalTrials":101,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1529,"PHASE4":1535,"NA":1537},{"trials":1524,"activeCount":74},[],{"trials":1526,"activeCount":74},[],{"trials":1528,"activeCount":74},[],{"trials":1530,"activeCount":74},[1531],{"nctId":901,"briefTitle":902,"status":80,"phases":1532,"primaryCompletion":904,"completion":904,"start":879,"enrollment":905,"conditions":1533,"interventions":1534},[66],[24,439],[890,908,909],{"trials":1536,"activeCount":74},[],{"trials":1538,"activeCount":74},[],{"intervention":909,"totalTrials":101,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1553,"NA":1555},{"trials":1542,"activeCount":74},[],{"trials":1544,"activeCount":74},[],{"trials":1546,"activeCount":74},[],{"trials":1548,"activeCount":74},[1549],{"nctId":901,"briefTitle":902,"status":80,"phases":1550,"primaryCompletion":904,"completion":904,"start":879,"enrollment":905,"conditions":1551,"interventions":1552},[66],[24,439],[890,908,909],{"trials":1554,"activeCount":74},[],{"trials":1556,"activeCount":74},[],{"intervention":1558,"totalTrials":101,"cells":1559},"Remifentanil",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1578,"NA":1580},{"trials":1561,"activeCount":74},[],{"trials":1563,"activeCount":74},[],{"trials":1565,"activeCount":74},[],{"trials":1567,"activeCount":74},[1568],{"nctId":1569,"briefTitle":1570,"status":80,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1577},"NCT01998165","A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised",[66],"2014-11","2013-11",80,[1576],"Anesthesia",[1558],{"trials":1579,"activeCount":74},[],{"trials":1581,"activeCount":74},[],{"intervention":1583,"totalTrials":101,"cells":1584},"Tramadol Hydrochloride Plus Acetaminophen",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1591,"PHASE4":1600,"NA":1602},{"trials":1586,"activeCount":74},[],{"trials":1588,"activeCount":74},[],{"trials":1590,"activeCount":74},[],{"trials":1592,"activeCount":74},[1593],{"nctId":1594,"briefTitle":1595,"status":80,"phases":1596,"primaryCompletion":446,"completion":446,"start":455,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT00736853","An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain",[66],321,[24],[1583,1583],{"trials":1601,"activeCount":74},[],{"trials":1603,"activeCount":74},[],{"intervention":1605,"totalTrials":101,"cells":1606},"Paliperidone extended-release",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1623,"NA":1625},{"trials":1608,"activeCount":74},[],{"trials":1610,"activeCount":74},[],{"trials":1612,"activeCount":74},[],{"trials":1614,"activeCount":74},[1615],{"nctId":1616,"briefTitle":1617,"status":80,"phases":1618,"primaryCompletion":1219,"completion":1219,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT01561898","A Long-Term Study of JNS007ER in Patients With Schizophrenia",[66],"2006-06",228,[21],[1605],{"trials":1624,"activeCount":74},[],{"trials":1626,"activeCount":74},[],{"intervention":1628,"totalTrials":101,"cells":1629},"Golimumab",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1648,"NA":1650},{"trials":1631,"activeCount":74},[],{"trials":1633,"activeCount":74},[],{"trials":1635,"activeCount":74},[],{"trials":1637,"activeCount":74},[1638],{"nctId":1639,"briefTitle":1640,"status":80,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1647},"NCT01863771","A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.",[66],"2016-01-29","2013-03-15",144,[1646],"Colitis, Ulcerative",[1628],{"trials":1649,"activeCount":74},[],{"trials":1651,"activeCount":74},[],{"intervention":1653,"totalTrials":35,"cells":1654},"bortezomib",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1670,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1656,"activeCount":74},[],{"trials":1658,"activeCount":74},[1659],{"nctId":1660,"briefTitle":1661,"status":80,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":280,"conditions":1665,"interventions":1666},"NCT02497378","A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma",[64],"2018-03-06","2015-07-10",[18],[1667,1668,1669],"JNJ-54767414","Bortezomib","Dexamethasone",{"trials":1671,"activeCount":74},[1672,1681],{"nctId":1673,"briefTitle":1674,"status":80,"phases":1675,"completion":1676,"start":1677,"enrollment":1678,"conditions":1679,"interventions":1680},"NCT00216697","An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I\u002FII Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy",[65],"2006-10","2005-03",13,[18],[1653],{"nctId":1682,"briefTitle":1683,"status":80,"phases":1684,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1691},"NCT00752518","A Japan Phase I\u002FII Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients",[64,65],"2006-01","2004-05",35,[1689,18,1690],"Refractory","Relapse",[1653],{"trials":1693,"activeCount":74},[],{"trials":1695,"activeCount":74},[],{"trials":1697,"activeCount":74},[],{"intervention":1699,"totalTrials":12,"cells":1700},"Topiramate",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1702,"activeCount":74},[],{"trials":1704,"activeCount":74},[],{"trials":1706,"activeCount":74},[1707,1716],{"nctId":1708,"briefTitle":1709,"status":80,"phases":1710,"primaryCompletion":915,"completion":915,"start":1711,"enrollment":1712,"conditions":1713,"interventions":1715},"NCT01799590","Continuous Treatment Study of Topiramate in Migraine Participants",[65],"2007-08",296,[1714],"Migraine",[1699],{"nctId":1717,"briefTitle":1718,"status":80,"phases":1719,"primaryCompletion":446,"completion":446,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT01081795","A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine",[65],"2007-04",387,[1714],[1699],{"trials":1725,"activeCount":74},[],{"trials":1727,"activeCount":74},[],{"trials":1729,"activeCount":74},[],{"intervention":1731,"totalTrials":12,"cells":1732},"CNTO 1959",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1746,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1734,"activeCount":74},[],{"trials":1736,"activeCount":74},[1737],{"nctId":1738,"briefTitle":1739,"status":80,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1745},"NCT01484587","A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis",[64],"2013-04-11","2011-08-22",24,[882],[1731],{"trials":1747,"activeCount":74},[1748],{"nctId":1749,"briefTitle":1750,"status":80,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":255,"enrollment":501,"conditions":1753,"interventions":1755},"NCT01845987","A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis",[65],"2014-09",[1754],"Palmoplantaris Pustulosis",[1731],{"trials":1757,"activeCount":74},[],{"trials":1759,"activeCount":74},[],{"trials":1761,"activeCount":74},[],{"intervention":1763,"totalTrials":12,"cells":1764},"Guselkumab Dose 1",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1779,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1766,"activeCount":74},[],{"trials":1768,"activeCount":74},[1769],{"nctId":1770,"briefTitle":1771,"status":80,"phases":1772,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1743,"conditions":1775,"interventions":1776},"NCT03536325","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants",[64],"2018-10-25","2018-05-31",[15],[1763,1777,1778],"Guselkumab Dose 2","Guselkumab Dose 3",{"trials":1780,"activeCount":74},[1781],{"nctId":1782,"briefTitle":1783,"status":80,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":591,"conditions":1788,"interventions":1790},"NCT04683029","A Study of Guselkumab in Participants With Systemic Sclerosis",[65],"2023-05-17","2024-07-09","2021-02-24",[1789],"Scleroderma, Systemic",[1763,1777],{"trials":1792,"activeCount":74},[],{"trials":1794,"activeCount":74},[],{"trials":1796,"activeCount":74},[],{"intervention":1777,"totalTrials":12,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1807,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1800,"activeCount":74},[],{"trials":1802,"activeCount":74},[1803],{"nctId":1770,"briefTitle":1771,"status":80,"phases":1804,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1743,"conditions":1805,"interventions":1806},[64],[15],[1763,1777,1778],{"trials":1808,"activeCount":74},[1809],{"nctId":1782,"briefTitle":1783,"status":80,"phases":1810,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":591,"conditions":1811,"interventions":1812},[65],[1789],[1763,1777],{"trials":1814,"activeCount":74},[],{"trials":1816,"activeCount":74},[],{"trials":1818,"activeCount":74},[],{"intervention":492,"totalTrials":101,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":74},[],{"trials":1824,"activeCount":74},[],{"trials":1826,"activeCount":74},[1827],{"nctId":484,"briefTitle":485,"status":80,"phases":1828,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":1829,"interventions":1830},[65],[27],[475,492,493],{"trials":1832,"activeCount":74},[],{"trials":1834,"activeCount":74},[],{"trials":1836,"activeCount":74},[],{"intervention":493,"totalTrials":101,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":74},[],{"trials":1842,"activeCount":74},[],{"trials":1844,"activeCount":74},[1845],{"nctId":484,"briefTitle":485,"status":80,"phases":1846,"primaryCompletion":487,"completion":487,"start":488,"enrollment":489,"conditions":1847,"interventions":1848},[65],[27],[475,492,493],{"trials":1850,"activeCount":74},[],{"trials":1852,"activeCount":74},[],{"trials":1854,"activeCount":74},[],{"intervention":1856,"totalTrials":101,"cells":1857},"Tramadol Hydrochloride; JNS013",{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1859,"activeCount":74},[],{"trials":1861,"activeCount":74},[],{"trials":1863,"activeCount":74},[1864],{"nctId":1865,"briefTitle":1866,"status":80,"phases":1867,"primaryCompletion":1475,"completion":1475,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1871},"NCT00752661","An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain",[65],"2007-06",119,[449,34],[1856],{"trials":1873,"activeCount":74},[],{"trials":1875,"activeCount":74},[],{"trials":1877,"activeCount":74},[],{"intervention":1879,"totalTrials":101,"cells":1880},"Tapentadol",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1882,"activeCount":74},[],{"trials":1884,"activeCount":74},[],{"trials":1886,"activeCount":74},[1887],{"nctId":1888,"briefTitle":1889,"status":80,"phases":1890,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1897},"NCT01124617","A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia",[65],"2011-04","2010-06",91,[24,1895,1896,437],"Diabetic Neuropathies","Neuralgia",[1879],{"trials":1899,"activeCount":74},[],{"trials":1901,"activeCount":74},[],{"trials":1903,"activeCount":74},[],{"intervention":1905,"totalTrials":101,"cells":1906},"Tapentadol Hydrochloride",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1923,"PHASE4":1925,"NA":1927},{"trials":1908,"activeCount":74},[],{"trials":1910,"activeCount":74},[],{"trials":1912,"activeCount":74},[1913],{"nctId":1914,"briefTitle":1915,"status":80,"phases":1916,"primaryCompletion":1917,"completion":1917,"start":1918,"enrollment":1893,"conditions":1919,"interventions":1922},"NCT01124604","An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants",[65],"2010-12","2010-04",[24,34,1920,1921],"Back Pain","Osteoarthritis, Knee",[1905],{"trials":1924,"activeCount":74},[],{"trials":1926,"activeCount":74},[],{"trials":1928,"activeCount":74},[],{"intervention":1930,"totalTrials":101,"cells":1931},"JNJ-39758979, 300 mg",{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1933,"activeCount":74},[],{"trials":1935,"activeCount":74},[],{"trials":1937,"activeCount":74},[1938],{"nctId":1939,"briefTitle":1940,"status":685,"phases":1941,"primaryCompletion":1942,"completion":1942,"start":812,"enrollment":1943,"conditions":1944,"interventions":1946},"NCT01497119","A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis",[65],"2012-02",88,[1945],"Dermatitis, Atopic",[1930,1947],"JNJ-39758979, 100 mg",{"trials":1949,"activeCount":74},[],{"trials":1951,"activeCount":74},[],{"trials":1953,"activeCount":74},[],{"intervention":1947,"totalTrials":101,"cells":1955},{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1957,"activeCount":74},[],{"trials":1959,"activeCount":74},[],{"trials":1961,"activeCount":74},[1962],{"nctId":1939,"briefTitle":1940,"status":685,"phases":1963,"primaryCompletion":1942,"completion":1942,"start":812,"enrollment":1943,"conditions":1964,"interventions":1965},[65],[1945],[1930,1947],{"trials":1967,"activeCount":74},[],{"trials":1969,"activeCount":74},[],{"trials":1971,"activeCount":74},[],{"intervention":1973,"totalTrials":101,"cells":1974},"AL-335",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1976,"activeCount":74},[],{"trials":1978,"activeCount":74},[],{"trials":1980,"activeCount":74},[1981],{"nctId":1982,"briefTitle":1983,"status":80,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":689,"conditions":1987,"interventions":1988},"NCT02993250","A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive",[65],"2018-05-07","2016-12-21",[27],[1973,1989,1990],"Odalasvir","Simeprevir",{"trials":1992,"activeCount":74},[],{"trials":1994,"activeCount":74},[],{"trials":1996,"activeCount":74},[],{"intervention":1989,"totalTrials":101,"cells":1998},{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2009,"PHASE4":2011,"NA":2013},{"trials":2000,"activeCount":74},[],{"trials":2002,"activeCount":74},[],{"trials":2004,"activeCount":74},[2005],{"nctId":1982,"briefTitle":1983,"status":80,"phases":2006,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":689,"conditions":2007,"interventions":2008},[65],[27],[1973,1989,1990],{"trials":2010,"activeCount":74},[],{"trials":2012,"activeCount":74},[],{"trials":2014,"activeCount":74},[],{"intervention":1990,"totalTrials":101,"cells":2016},{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2018,"activeCount":74},[],{"trials":2020,"activeCount":74},[],{"trials":2022,"activeCount":74},[2023],{"nctId":1982,"briefTitle":1983,"status":80,"phases":2024,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":689,"conditions":2025,"interventions":2026},[65],[27],[1973,1989,1990],{"trials":2028,"activeCount":74},[],{"trials":2030,"activeCount":74},[],{"trials":2032,"activeCount":74},[],{"intervention":2034,"totalTrials":101,"cells":2035},"Intranasal esketamine",{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2037,"activeCount":74},[],{"trials":2039,"activeCount":74},[],{"trials":2041,"activeCount":74},[2042],{"nctId":2043,"briefTitle":2044,"status":80,"phases":2045,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT02918318","A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression",[65],"2019-08-19","2019-12-13","2016-12-12",202,[2051],"Depression",[2034,2034,2034],{"trials":2054,"activeCount":74},[],{"trials":2056,"activeCount":74},[],{"trials":2058,"activeCount":74},[],{"intervention":645,"totalTrials":101,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2062,"activeCount":74},[],{"trials":2064,"activeCount":74},[],{"trials":2066,"activeCount":74},[2067],{"nctId":635,"briefTitle":636,"status":80,"phases":2068,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":2069,"interventions":2070},[65],[643],[617,645],{"trials":2072,"activeCount":74},[],{"trials":2074,"activeCount":74},[],{"trials":2076,"activeCount":74},[],{"intervention":2078,"totalTrials":101,"cells":2079},"Nesiritide",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2081,"activeCount":74},[],{"trials":2083,"activeCount":74},[],{"trials":2085,"activeCount":74},[2086],{"nctId":2087,"briefTitle":2088,"status":80,"phases":2089,"primaryCompletion":455,"completion":302,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2094},"NCT00490724","An Exploratory Study of Nesiritide in Participants With Acute Heart Failure",[65],"2007-03",67,[2093],"Heart Failure, Congestive",[2078,2078,2095],"Nesritide",{"trials":2097,"activeCount":74},[],{"trials":2099,"activeCount":74},[],{"trials":2101,"activeCount":74},[],{"intervention":2095,"totalTrials":101,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2105,"activeCount":74},[],{"trials":2107,"activeCount":74},[],{"trials":2109,"activeCount":74},[2110],{"nctId":2087,"briefTitle":2088,"status":80,"phases":2111,"primaryCompletion":455,"completion":302,"start":2090,"enrollment":2091,"conditions":2112,"interventions":2113},[65],[2093],[2078,2078,2095],{"trials":2115,"activeCount":74},[],{"trials":2117,"activeCount":74},[],{"trials":2119,"activeCount":74},[],{"intervention":2121,"totalTrials":101,"cells":2122},"CNTO 2476",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2124,"activeCount":74},[],{"trials":2126,"activeCount":74},[],{"trials":2128,"activeCount":74},[2129],{"nctId":2130,"briefTitle":2131,"status":2132,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":74,"conditions":2137,"interventions":2141},"NCT02895815","Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)","WITHDRAWN",[65],"2021-02-20","2022-08-19","2018-04-09",[2138,2139,2140],"Visual Acuity","Geographic Atrophy","Macular Degeneration",[2121,2121],{"trials":2143,"activeCount":74},[],{"trials":2145,"activeCount":74},[],{"trials":2147,"activeCount":74},[],{"intervention":2149,"totalTrials":101,"cells":2150},"TMC207",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2152,"activeCount":74},[],{"trials":2154,"activeCount":74},[],{"trials":2156,"activeCount":74},[2157],{"nctId":2158,"briefTitle":2159,"status":80,"phases":2160,"primaryCompletion":2161,"completion":2161,"start":2162,"enrollment":11,"conditions":2163,"interventions":2165},"NCT02365623","An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)",[65],"2018-11-08","2015-02-18",[2164],"Tuberculosis, Multidrug-Resistant",[2149,2166],"Background Regimen",{"trials":2168,"activeCount":74},[],{"trials":2170,"activeCount":74},[],{"trials":2172,"activeCount":74},[],{"intervention":2166,"totalTrials":101,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":74},[],{"trials":2178,"activeCount":74},[],{"trials":2180,"activeCount":74},[2181],{"nctId":2158,"briefTitle":2159,"status":80,"phases":2182,"primaryCompletion":2161,"completion":2161,"start":2162,"enrollment":11,"conditions":2183,"interventions":2184},[65],[2164],[2149,2166],{"trials":2186,"activeCount":74},[],{"trials":2188,"activeCount":74},[],{"trials":2190,"activeCount":74},[],{"intervention":2192,"totalTrials":101,"cells":2193},"paliperidone",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2195,"activeCount":74},[],{"trials":2197,"activeCount":74},[],{"trials":2199,"activeCount":74},[2200],{"nctId":2201,"briefTitle":2202,"status":80,"phases":2203,"completion":411,"start":2204,"enrollment":2205,"conditions":2206,"interventions":2207},"NCT00257023","An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia",[65],"2005-02",52,[21],[2192],{"trials":2209,"activeCount":74},[],{"trials":2211,"activeCount":74},[],{"trials":2213,"activeCount":74},[],{"intervention":2215,"totalTrials":101,"cells":2216},"Amivantamab",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2218,"activeCount":74},[],{"trials":2220,"activeCount":74},[],{"trials":2222,"activeCount":74},[2223],{"nctId":2224,"briefTitle":2225,"status":685,"phases":2226,"primaryCompletion":2227,"completion":2227,"start":2228,"enrollment":2229,"conditions":2230,"interventions":2233},"NCT04945733","A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer",[65],"2023-07-03","2021-08-30",62,[2231,2232],"Stomach Neoplasms","Esophageal Neoplasms",[2215],{"trials":2235,"activeCount":74},[],{"trials":2237,"activeCount":74},[],{"trials":2239,"activeCount":74},[],{"intervention":2241,"totalTrials":101,"cells":2242},"Risperidone long acting injectable",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2244,"activeCount":74},[],{"trials":2246,"activeCount":74},[],{"trials":2248,"activeCount":74},[2249],{"nctId":2250,"briefTitle":2251,"status":80,"phases":2252,"completion":2253,"start":2254,"enrollment":2255,"conditions":2256,"interventions":2257},"NCT00653406","A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients",[64,65],"2003-10","2002-11",29,[21],[2241],{"trials":2259,"activeCount":74},[],{"trials":2261,"activeCount":74},[],{"trials":2263,"activeCount":74},[],{"intervention":2265,"totalTrials":101,"cells":2266},"Tapentadol PR",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2271,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2268,"activeCount":74},[],{"trials":2270,"activeCount":74},[],{"trials":2272,"activeCount":74},[2273],{"nctId":2274,"briefTitle":2275,"status":80,"phases":2276,"primaryCompletion":488,"completion":488,"start":425,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT00805142","Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants",[65],78,[24,459],[2265],{"trials":2281,"activeCount":74},[],{"trials":2283,"activeCount":74},[],{"trials":2285,"activeCount":74},[],{"intervention":2287,"totalTrials":101,"cells":2288},"doxorubicin hydrochloride",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2290,"activeCount":74},[],{"trials":2292,"activeCount":74},[],{"trials":2294,"activeCount":74},[2295],{"nctId":2296,"briefTitle":2297,"status":80,"phases":2298,"completion":2299,"start":2300,"enrollment":2301,"conditions":2302,"interventions":2304},"NCT00216645","Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy",[65],"2006-11","2005-01",74,[2303],"Ovarian Neoplasms",[2287],{"trials":2306,"activeCount":74},[],{"trials":2308,"activeCount":74},[],{"trials":2310,"activeCount":74},[],{"intervention":1669,"totalTrials":12,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2314,"activeCount":74},[],{"trials":2316,"activeCount":74},[2317,2321],{"nctId":1660,"briefTitle":1661,"status":80,"phases":2318,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":280,"conditions":2319,"interventions":2320},[64],[18],[1667,1668,1669],{"nctId":2322,"briefTitle":2323,"status":80,"phases":2324,"primaryCompletion":2325,"completion":2326,"start":2327,"enrollment":25,"conditions":2328,"interventions":2329},"NCT02918331","A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation",[64],"2017-10","2020-03","2016-09",[18],[2330,2331,1669],"Daratumumab","Lenalidomide",{"trials":2333,"activeCount":74},[],{"trials":2335,"activeCount":74},[],{"trials":2337,"activeCount":74},[],{"trials":2339,"activeCount":74},[],{"intervention":2330,"totalTrials":12,"cells":2341},{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2343,"activeCount":74},[],{"trials":2345,"activeCount":74},[2346,2353],{"nctId":2347,"briefTitle":2348,"status":80,"phases":2349,"primaryCompletion":344,"completion":344,"start":2350,"enrollment":22,"conditions":2351,"interventions":2352},"NCT02116569","A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma",[64],"2014-04",[18],[2330],{"nctId":2322,"briefTitle":2323,"status":80,"phases":2354,"primaryCompletion":2325,"completion":2326,"start":2327,"enrollment":25,"conditions":2355,"interventions":2356},[64],[18],[2330,2331,1669],{"trials":2358,"activeCount":74},[],{"trials":2360,"activeCount":74},[],{"trials":2362,"activeCount":74},[],{"trials":2364,"activeCount":74},[],{"intervention":2366,"totalTrials":101,"cells":2367},"PCI-32765",{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2369,"activeCount":74},[],{"trials":2371,"activeCount":74},[2372],{"nctId":2373,"briefTitle":2374,"status":80,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":2379,"conditions":2380,"interventions":2382},"NCT01704963","A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms",[64],"2015-11-20","2017-02-01","2012-09-12",15,[2381],"Recurrent Mature B-cell Neoplasms",[2366],{"trials":2384,"activeCount":74},[],{"trials":2386,"activeCount":74},[],{"trials":2388,"activeCount":74},[],{"trials":2390,"activeCount":74},[],{"intervention":2392,"totalTrials":101,"cells":2393},"JNJ-26866138 0.7 mg\u002Fm2",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2395,"activeCount":74},[],{"trials":2397,"activeCount":74},[2398],{"nctId":2399,"briefTitle":2400,"status":80,"phases":2401,"primaryCompletion":1892,"completion":1892,"start":302,"enrollment":2402,"conditions":2403,"interventions":2404},"NCT00985959","A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)",[64],101,[18],[2392,2405,2406,2407,202],"JNJ-26866138 1.0 mg\u002Fm2","JNJ-26866138 1.3 mg\u002Fm2","Melphalan",{"trials":2409,"activeCount":74},[],{"trials":2411,"activeCount":74},[],{"trials":2413,"activeCount":74},[],{"trials":2415,"activeCount":74},[],{"intervention":2405,"totalTrials":101,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":74},[],{"trials":2421,"activeCount":74},[2422],{"nctId":2399,"briefTitle":2400,"status":80,"phases":2423,"primaryCompletion":1892,"completion":1892,"start":302,"enrollment":2402,"conditions":2424,"interventions":2425},[64],[18],[2392,2405,2406,2407,202],{"trials":2427,"activeCount":74},[],{"trials":2429,"activeCount":74},[],{"trials":2431,"activeCount":74},[],{"trials":2433,"activeCount":74},[],{"intervention":2406,"totalTrials":101,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":74},[],{"trials":2439,"activeCount":74},[2440],{"nctId":2399,"briefTitle":2400,"status":80,"phases":2441,"primaryCompletion":1892,"completion":1892,"start":302,"enrollment":2402,"conditions":2442,"interventions":2443},[64],[18],[2392,2405,2406,2407,202],{"trials":2445,"activeCount":74},[],{"trials":2447,"activeCount":74},[],{"trials":2449,"activeCount":74},[],{"trials":2451,"activeCount":74},[],{"intervention":2407,"totalTrials":101,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":74},[],{"trials":2457,"activeCount":74},[2458],{"nctId":2399,"briefTitle":2400,"status":80,"phases":2459,"primaryCompletion":1892,"completion":1892,"start":302,"enrollment":2402,"conditions":2460,"interventions":2461},[64],[18],[2392,2405,2406,2407,202],{"trials":2463,"activeCount":74},[],{"trials":2465,"activeCount":74},[],{"trials":2467,"activeCount":74},[],{"trials":2469,"activeCount":74},[],{"intervention":2471,"totalTrials":101,"cells":2472},"Siltuximab",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2484,"PHASE3":2486,"PHASE4":2488,"NA":2490},{"trials":2474,"activeCount":74},[],{"trials":2476,"activeCount":74},[2477],{"nctId":2478,"briefTitle":2479,"status":685,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":487,"enrollment":22,"conditions":2482,"interventions":2483},"NCT01309412","A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma",[64],"2012-12",[18],[2471],{"trials":2485,"activeCount":74},[],{"trials":2487,"activeCount":74},[],{"trials":2489,"activeCount":74},[],{"trials":2491,"activeCount":74},[],{"intervention":2493,"totalTrials":101,"cells":2494},"ExPEC10V",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2496,"activeCount":74},[],{"trials":2498,"activeCount":74},[2499],{"nctId":2500,"briefTitle":2501,"status":80,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":1743,"conditions":2505,"interventions":2506},"NCT04306302","A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults",[64],"2020-12-24","2020-03-13",[15],[2493],{"trials":2508,"activeCount":74},[],{"trials":2510,"activeCount":74},[],{"trials":2512,"activeCount":74},[],{"trials":2514,"activeCount":74},[],{"intervention":2516,"totalTrials":101,"cells":2517},"JNJ 10229570-AAA 1.2% cream",{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2519,"activeCount":74},[],{"trials":2521,"activeCount":74},[2522],{"nctId":2523,"briefTitle":2524,"status":80,"phases":2525,"primaryCompletion":256,"completion":256,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2530},"NCT01494714","A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants",[64],"2011-08",30,[2529],"Healthy Volunteers",[2516,2531,2532,2533,2534],"JNJ 10229570-AAA 2.4% cream","JNJ 10229570-AAA 3.6% cream","Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA","Petroleum jelly",{"trials":2536,"activeCount":74},[],{"trials":2538,"activeCount":74},[],{"trials":2540,"activeCount":74},[],{"trials":2542,"activeCount":74},[],{"intervention":2531,"totalTrials":101,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":74},[],{"trials":2548,"activeCount":74},[2549],{"nctId":2523,"briefTitle":2524,"status":80,"phases":2550,"primaryCompletion":256,"completion":256,"start":2526,"enrollment":2527,"conditions":2551,"interventions":2552},[64],[2529],[2516,2531,2532,2533,2534],{"trials":2554,"activeCount":74},[],{"trials":2556,"activeCount":74},[],{"trials":2558,"activeCount":74},[],{"trials":2560,"activeCount":74},[],{"intervention":2532,"totalTrials":101,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2571,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":74},[],{"trials":2566,"activeCount":74},[2567],{"nctId":2523,"briefTitle":2524,"status":80,"phases":2568,"primaryCompletion":256,"completion":256,"start":2526,"enrollment":2527,"conditions":2569,"interventions":2570},[64],[2529],[2516,2531,2532,2533,2534],{"trials":2572,"activeCount":74},[],{"trials":2574,"activeCount":74},[],{"trials":2576,"activeCount":74},[],{"trials":2578,"activeCount":74},[],{"intervention":2533,"totalTrials":101,"cells":2580},{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2582,"activeCount":74},[],{"trials":2584,"activeCount":74},[2585],{"nctId":2523,"briefTitle":2524,"status":80,"phases":2586,"primaryCompletion":256,"completion":256,"start":2526,"enrollment":2527,"conditions":2587,"interventions":2588},[64],[2529],[2516,2531,2532,2533,2534],{"trials":2590,"activeCount":74},[],{"trials":2592,"activeCount":74},[],{"trials":2594,"activeCount":74},[],{"trials":2596,"activeCount":74},[],{"intervention":2534,"totalTrials":101,"cells":2598},{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2600,"activeCount":74},[],{"trials":2602,"activeCount":74},[2603],{"nctId":2523,"briefTitle":2524,"status":80,"phases":2604,"primaryCompletion":256,"completion":256,"start":2526,"enrollment":2527,"conditions":2605,"interventions":2606},[64],[2529],[2516,2531,2532,2533,2534],{"trials":2608,"activeCount":74},[],{"trials":2610,"activeCount":74},[],{"trials":2612,"activeCount":74},[],{"trials":2614,"activeCount":74},[],{"intervention":2616,"totalTrials":101,"cells":2617},"CR6261",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2619,"activeCount":74},[],{"trials":2621,"activeCount":74},[2622],{"nctId":2623,"briefTitle":2624,"status":2132,"phases":2625,"primaryCompletion":2626,"completion":2350,"start":2627,"enrollment":74,"conditions":2628,"interventions":2629},"NCT02016066","A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants",[64],"2014-01","2013-12",[15],[2616],{"trials":2631,"activeCount":74},[],{"trials":2633,"activeCount":74},[],{"trials":2635,"activeCount":74},[],{"trials":2637,"activeCount":74},[],{"intervention":2639,"totalTrials":101,"cells":2640},"DARA SC",{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2654,"PHASE3":2656,"PHASE4":2658,"NA":2660},{"trials":2642,"activeCount":74},[],{"trials":2644,"activeCount":74},[2645],{"nctId":2646,"briefTitle":2647,"status":80,"phases":2648,"primaryCompletion":2649,"completion":2650,"start":2651,"enrollment":11,"conditions":2652,"interventions":2653},"NCT03242889","A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma",[64],"2017-11-01","2023-02-10","2017-08-10",[18],[2639],{"trials":2655,"activeCount":74},[],{"trials":2657,"activeCount":74},[],{"trials":2659,"activeCount":74},[],{"trials":2661,"activeCount":74},[],{"intervention":1667,"totalTrials":101,"cells":2663},{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2672,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2665,"activeCount":74},[],{"trials":2667,"activeCount":74},[2668],{"nctId":1660,"briefTitle":1661,"status":80,"phases":2669,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":280,"conditions":2670,"interventions":2671},[64],[18],[1667,1668,1669],{"trials":2673,"activeCount":74},[],{"trials":2675,"activeCount":74},[],{"trials":2677,"activeCount":74},[],{"trials":2679,"activeCount":74},[],{"intervention":2681,"totalTrials":101,"cells":2682},"JNJ-56021927 60 Milligram",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2697,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2684,"activeCount":74},[],{"trials":2686,"activeCount":74},[2687],{"nctId":2688,"briefTitle":2689,"status":80,"phases":2690,"primaryCompletion":651,"completion":651,"start":2691,"enrollment":2692,"conditions":2693,"interventions":2694},"NCT02835508","Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants",[64],"2016-06",18,[15],[2681,2695,2696],"JNJ-56021927 120 Milligram","JNJ-56021927 240 Milligram",{"trials":2698,"activeCount":74},[],{"trials":2700,"activeCount":74},[],{"trials":2702,"activeCount":74},[],{"trials":2704,"activeCount":74},[],{"intervention":2695,"totalTrials":101,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":74},[],{"trials":2710,"activeCount":74},[2711],{"nctId":2688,"briefTitle":2689,"status":80,"phases":2712,"primaryCompletion":651,"completion":651,"start":2691,"enrollment":2692,"conditions":2713,"interventions":2714},[64],[15],[2681,2695,2696],{"trials":2716,"activeCount":74},[],{"trials":2718,"activeCount":74},[],{"trials":2720,"activeCount":74},[],{"trials":2722,"activeCount":74},[],{"intervention":2696,"totalTrials":101,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2733,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":74},[],{"trials":2728,"activeCount":74},[2729],{"nctId":2688,"briefTitle":2689,"status":80,"phases":2730,"primaryCompletion":651,"completion":651,"start":2691,"enrollment":2692,"conditions":2731,"interventions":2732},[64],[15],[2681,2695,2696],{"trials":2734,"activeCount":74},[],{"trials":2736,"activeCount":74},[],{"trials":2738,"activeCount":74},[],{"trials":2740,"activeCount":74},[],{"intervention":2742,"totalTrials":101,"cells":2743},"JNJ-64565111",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2745,"activeCount":74},[],{"trials":2747,"activeCount":74},[2748],{"nctId":2749,"briefTitle":2750,"status":685,"phases":2751,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":2754,"conditions":2755,"interventions":2756},"NCT03618160","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants",[64],"2019-06-21","2018-08-06",42,[15],[2742],{"trials":2758,"activeCount":74},[],{"trials":2760,"activeCount":74},[],{"trials":2762,"activeCount":74},[],{"trials":2764,"activeCount":74},[],{"intervention":2766,"totalTrials":101,"cells":2767},"JNJ-64304500",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2781,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2769,"activeCount":74},[],{"trials":2771,"activeCount":74},[2772],{"nctId":2773,"briefTitle":2774,"status":80,"phases":2775,"primaryCompletion":2776,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2780},"NCT03002025","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants",[64],"2017-09-09","2017-01-10",48,[15],[2766],{"trials":2782,"activeCount":74},[],{"trials":2784,"activeCount":74},[],{"trials":2786,"activeCount":74},[],{"trials":2788,"activeCount":74},[],{"intervention":2790,"totalTrials":101,"cells":2791},"Oromucosal Nicotine Spray",{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2793,"activeCount":74},[],{"trials":2795,"activeCount":74},[2796],{"nctId":2797,"briefTitle":2798,"status":80,"phases":2799,"primaryCompletion":2800,"completion":2800,"start":2801,"enrollment":1743,"conditions":2802,"interventions":2803},"NCT03398876","A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers",[64],"2018-04-16","2017-12-22",[15],[2790,2804],"Nicotine Gum",{"trials":2806,"activeCount":74},[],{"trials":2808,"activeCount":74},[],{"trials":2810,"activeCount":74},[],{"trials":2812,"activeCount":74},[],{"intervention":2804,"totalTrials":101,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2823,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":74},[],{"trials":2818,"activeCount":74},[2819],{"nctId":2797,"briefTitle":2798,"status":80,"phases":2820,"primaryCompletion":2800,"completion":2800,"start":2801,"enrollment":1743,"conditions":2821,"interventions":2822},[64],[15],[2790,2804],{"trials":2824,"activeCount":74},[],{"trials":2826,"activeCount":74},[],{"trials":2828,"activeCount":74},[],{"trials":2830,"activeCount":74},[],{"intervention":2832,"totalTrials":101,"cells":2833},"ALS-008176",{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2847,"PHASE3":2849,"PHASE4":2851,"NA":2853},{"trials":2835,"activeCount":74},[],{"trials":2837,"activeCount":74},[2838],{"nctId":2839,"briefTitle":2840,"status":80,"phases":2841,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":1743,"conditions":2844,"interventions":2846},"NCT02478333","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants",[64],"2015-07","2015-05",[2845],"Respiratory Syncytial Virus Infections",[2832,2832,2832],{"trials":2848,"activeCount":74},[],{"trials":2850,"activeCount":74},[],{"trials":2852,"activeCount":74},[],{"trials":2854,"activeCount":74},[],{"intervention":2856,"totalTrials":101,"cells":2857},"CR8020",{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2868,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2859,"activeCount":74},[],{"trials":2861,"activeCount":74},[2862],{"nctId":2863,"briefTitle":2864,"status":2132,"phases":2865,"primaryCompletion":2626,"completion":2350,"start":2627,"enrollment":74,"conditions":2866,"interventions":2867},"NCT02015533","A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants",[64],[15],[2856],{"trials":2869,"activeCount":74},[],{"trials":2871,"activeCount":74},[],{"trials":2873,"activeCount":74},[],{"trials":2875,"activeCount":74},[],{"intervention":2877,"totalTrials":101,"cells":2878},"JNJ-75220795",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2892,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2880,"activeCount":74},[],{"trials":2882,"activeCount":74},[2883],{"nctId":2884,"briefTitle":2885,"status":685,"phases":2886,"primaryCompletion":2887,"completion":2887,"start":2888,"enrollment":22,"conditions":2889,"interventions":2891},"NCT05039710","A Study of JNJ-75220795 in Japanese Participants",[64],"2023-02-17","2021-11-08",[2890],"Fatty Liver",[2877],{"trials":2893,"activeCount":74},[],{"trials":2895,"activeCount":74},[],{"trials":2897,"activeCount":74},[],{"trials":2899,"activeCount":74},[],{"intervention":2901,"totalTrials":101,"cells":2902},"Ad26.COV2.S",{"EARLY_PHASE1":2903,"PHASE1":2905,"PHASE2":2916,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2904,"activeCount":74},[],{"trials":2906,"activeCount":74},[2907],{"nctId":2908,"briefTitle":2909,"status":80,"phases":2910,"primaryCompletion":160,"completion":2911,"start":2912,"enrollment":2913,"conditions":2914,"interventions":2915},"NCT04509947","A Study of Ad26.COV2.S in Adults (COVID-19)",[64],"2021-11-16","2020-08-11",250,[15],[2901],{"trials":2917,"activeCount":74},[],{"trials":2919,"activeCount":74},[],{"trials":2921,"activeCount":74},[],{"trials":2923,"activeCount":74},[],{"intervention":2925,"totalTrials":101,"cells":2926},"JNJ-63723283",{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2942,"PHASE3":2944,"PHASE4":2946,"NA":2948},{"trials":2928,"activeCount":74},[],{"trials":2930,"activeCount":74},[2931],{"nctId":2932,"briefTitle":2933,"status":80,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":2937,"conditions":2938,"interventions":2940},"NCT03547037","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers",[64],"2022-07-04","2018-08-31",22,[2939],"Neoplasm",[2925,2941],"Erdafitinib",{"trials":2943,"activeCount":74},[],{"trials":2945,"activeCount":74},[],{"trials":2947,"activeCount":74},[],{"trials":2949,"activeCount":74},[],{"intervention":2941,"totalTrials":101,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2960,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2953,"activeCount":74},[],{"trials":2955,"activeCount":74},[2956],{"nctId":2932,"briefTitle":2933,"status":80,"phases":2957,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":2937,"conditions":2958,"interventions":2959},[64],[2939],[2925,2941],{"trials":2961,"activeCount":74},[],{"trials":2963,"activeCount":74},[],{"trials":2965,"activeCount":74},[],{"trials":2967,"activeCount":74},[],{"intervention":2969,"totalTrials":101,"cells":2970},"JNJ-0440",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2983,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2972,"activeCount":74},[],{"trials":2974,"activeCount":74},[2975],{"nctId":2976,"briefTitle":2977,"status":685,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":2980,"enrollment":641,"conditions":2981,"interventions":2982},"NCT03915886","A Study of JNJ-64530440 in Healthy Japanese Male Participants",[64],"2019-07-17","2019-04-15",[15],[2969],{"trials":2984,"activeCount":74},[],{"trials":2986,"activeCount":74},[],{"trials":2988,"activeCount":74},[],{"trials":2990,"activeCount":74},[],{"intervention":2992,"totalTrials":101,"cells":2993},"CNTO 3649 10 mcg\u002Fkg",{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":2995,"activeCount":74},[],{"trials":2997,"activeCount":74},[2998],{"nctId":2999,"briefTitle":3000,"status":80,"phases":3001,"primaryCompletion":433,"completion":433,"start":488,"enrollment":3002,"conditions":3003,"interventions":3005},"NCT02224118","Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus",[64],64,[15,3004],"Diabetes Mellitus, Type 2",[2992,3006,3007,3008],"CNT0 3649 30 mcg\u002Fkg","CNTO 3649 100 mcg\u002Fkg","CNTO 3649 300 mcg\u002Fkg",{"trials":3010,"activeCount":74},[],{"trials":3012,"activeCount":74},[],{"trials":3014,"activeCount":74},[],{"trials":3016,"activeCount":74},[],{"intervention":3006,"totalTrials":101,"cells":3018},{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3027,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3020,"activeCount":74},[],{"trials":3022,"activeCount":74},[3023],{"nctId":2999,"briefTitle":3000,"status":80,"phases":3024,"primaryCompletion":433,"completion":433,"start":488,"enrollment":3002,"conditions":3025,"interventions":3026},[64],[15,3004],[2992,3006,3007,3008],{"trials":3028,"activeCount":74},[],{"trials":3030,"activeCount":74},[],{"trials":3032,"activeCount":74},[],{"trials":3034,"activeCount":74},[],{"intervention":3007,"totalTrials":101,"cells":3036},{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3038,"activeCount":74},[],{"trials":3040,"activeCount":74},[3041],{"nctId":2999,"briefTitle":3000,"status":80,"phases":3042,"primaryCompletion":433,"completion":433,"start":488,"enrollment":3002,"conditions":3043,"interventions":3044},[64],[15,3004],[2992,3006,3007,3008],{"trials":3046,"activeCount":74},[],{"trials":3048,"activeCount":74},[],{"trials":3050,"activeCount":74},[],{"trials":3052,"activeCount":74},[],{"intervention":3008,"totalTrials":101,"cells":3054},{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3063,"PHASE3":3065,"PHASE4":3067,"NA":3069},{"trials":3056,"activeCount":74},[],{"trials":3058,"activeCount":74},[3059],{"nctId":2999,"briefTitle":3000,"status":80,"phases":3060,"primaryCompletion":433,"completion":433,"start":488,"enrollment":3002,"conditions":3061,"interventions":3062},[64],[15,3004],[2992,3006,3007,3008],{"trials":3064,"activeCount":74},[],{"trials":3066,"activeCount":74},[],{"trials":3068,"activeCount":74},[],{"trials":3070,"activeCount":74},[],{"intervention":3072,"totalTrials":101,"cells":3073},"Macitentan Dose 1",{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3075,"activeCount":74},[],{"trials":3077,"activeCount":74},[3078],{"nctId":3079,"briefTitle":3080,"status":80,"phases":3081,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":1743,"conditions":3084,"interventions":3085},"NCT04500808","A Study of Macitentan, in Healthy Japanese Male Participants",[64],"2020-12-14","2020-07-21",[15],[3072,3086,3087],"Macitentan Dose 2","Macitentan Dose 3",{"trials":3089,"activeCount":74},[],{"trials":3091,"activeCount":74},[],{"trials":3093,"activeCount":74},[],{"trials":3095,"activeCount":74},[],{"intervention":3086,"totalTrials":101,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3106,"PHASE3":3108,"PHASE4":3110,"NA":3112},{"trials":3099,"activeCount":74},[],{"trials":3101,"activeCount":74},[3102],{"nctId":3079,"briefTitle":3080,"status":80,"phases":3103,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":1743,"conditions":3104,"interventions":3105},[64],[15],[3072,3086,3087],{"trials":3107,"activeCount":74},[],{"trials":3109,"activeCount":74},[],{"trials":3111,"activeCount":74},[],{"trials":3113,"activeCount":74},[],{"intervention":3087,"totalTrials":101,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3124,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3117,"activeCount":74},[],{"trials":3119,"activeCount":74},[3120],{"nctId":3079,"briefTitle":3080,"status":80,"phases":3121,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":1743,"conditions":3122,"interventions":3123},[64],[15],[3072,3086,3087],{"trials":3125,"activeCount":74},[],{"trials":3127,"activeCount":74},[],{"trials":3129,"activeCount":74},[],{"trials":3131,"activeCount":74},[],{"intervention":3133,"totalTrials":101,"cells":3134},"JNJ-56021927",{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3136,"activeCount":74},[],{"trials":3138,"activeCount":74},[3139],{"nctId":3140,"briefTitle":3141,"status":80,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":11,"conditions":3145,"interventions":3147},"NCT02162836","A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer",[64],"2019-05-27","2014-06-27",[3146],"Prostatic Neoplasms, Castration-Resistant",[3133],{"trials":3149,"activeCount":74},[],{"trials":3151,"activeCount":74},[],{"trials":3153,"activeCount":74},[],{"trials":3155,"activeCount":74},[],{"intervention":3157,"totalTrials":101,"cells":3158},"JNJ-54861911",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3170,"PHASE3":3172,"PHASE4":3174,"NA":3176},{"trials":3160,"activeCount":74},[],{"trials":3162,"activeCount":74},[3163],{"nctId":3164,"briefTitle":3165,"status":80,"phases":3166,"primaryCompletion":652,"completion":652,"start":3167,"enrollment":1743,"conditions":3168,"interventions":3169},"NCT02180269","A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants",[64],"2014-06",[15],[3157,3157,3157],{"trials":3171,"activeCount":74},[],{"trials":3173,"activeCount":74},[],{"trials":3175,"activeCount":74},[],{"trials":3177,"activeCount":74},[],{"intervention":3179,"totalTrials":101,"cells":3180},"JNJ-42847922, 5 mg",{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3195,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3182,"activeCount":74},[],{"trials":3184,"activeCount":74},[3185],{"nctId":3186,"briefTitle":3187,"status":80,"phases":3188,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":1743,"conditions":3191,"interventions":3192},"NCT02555124","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants",[64],"2015-10-31","2015-09-12",[15],[3179,3193,3194],"JNJ-42847922, 20 mg","JNJ-42847922, 40 mg",{"trials":3196,"activeCount":74},[],{"trials":3198,"activeCount":74},[],{"trials":3200,"activeCount":74},[],{"trials":3202,"activeCount":74},[],{"intervention":3193,"totalTrials":101,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":74},[],{"trials":3208,"activeCount":74},[3209],{"nctId":3186,"briefTitle":3187,"status":80,"phases":3210,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":1743,"conditions":3211,"interventions":3212},[64],[15],[3179,3193,3194],{"trials":3214,"activeCount":74},[],{"trials":3216,"activeCount":74},[],{"trials":3218,"activeCount":74},[],{"trials":3220,"activeCount":74},[],{"intervention":3194,"totalTrials":101,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":74},[],{"trials":3226,"activeCount":74},[3227],{"nctId":3186,"briefTitle":3187,"status":80,"phases":3228,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":1743,"conditions":3229,"interventions":3230},[64],[15],[3179,3193,3194],{"trials":3232,"activeCount":74},[],{"trials":3234,"activeCount":74},[],{"trials":3236,"activeCount":74},[],{"trials":3238,"activeCount":74},[],{"intervention":2331,"totalTrials":101,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":74},[],{"trials":3244,"activeCount":74},[3245],{"nctId":2322,"briefTitle":2323,"status":80,"phases":3246,"primaryCompletion":2325,"completion":2326,"start":2327,"enrollment":25,"conditions":3247,"interventions":3248},[64],[18],[2330,2331,1669],{"trials":3250,"activeCount":74},[],{"trials":3252,"activeCount":74},[],{"trials":3254,"activeCount":74},[],{"trials":3256,"activeCount":74},[],{"intervention":3258,"totalTrials":101,"cells":3259},"Talquetamab",{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3261,"activeCount":74},[],{"trials":3263,"activeCount":74},[3264],{"nctId":3265,"briefTitle":3266,"status":80,"phases":3267,"primaryCompletion":3268,"completion":3269,"start":3270,"enrollment":2379,"conditions":3271,"interventions":3272},"NCT04773522","A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma",[64],"2022-10-14","2025-09-04","2021-05-20",[18],[3258],{"trials":3274,"activeCount":74},[],{"trials":3276,"activeCount":74},[],{"trials":3278,"activeCount":74},[],{"trials":3280,"activeCount":74},[],{"intervention":3282,"totalTrials":101,"cells":3283},"JNJ-212082",{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3297,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3285,"activeCount":74},[],{"trials":3287,"activeCount":74},[3288],{"nctId":3289,"briefTitle":3290,"status":80,"phases":3291,"primaryCompletion":3292,"completion":3292,"start":3293,"enrollment":3294,"conditions":3295,"interventions":3296},"NCT01186484","Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer",[64],"2014-10-02","2010-06-01",27,[197],[3282],{"trials":3298,"activeCount":74},[],{"trials":3300,"activeCount":74},[],{"trials":3302,"activeCount":74},[],{"trials":3304,"activeCount":74},[],{"intervention":3306,"totalTrials":101,"cells":3307},"JNJ 10229570-AAA 1.2%",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3309,"activeCount":74},[],{"trials":3311,"activeCount":74},[3312],{"nctId":3313,"briefTitle":3314,"status":80,"phases":3315,"primaryCompletion":812,"completion":812,"start":2526,"enrollment":2692,"conditions":3316,"interventions":3318},"NCT01492647","A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris",[64],[3317],"Acne Vulgaris",[3306,3319,3320],"JNJ 10229570-AAA 3.6%","Color-matched vehicle containing 0 mg of JNJ 10229570-AAA",{"trials":3322,"activeCount":74},[],{"trials":3324,"activeCount":74},[],{"trials":3326,"activeCount":74},[],{"trials":3328,"activeCount":74},[],{"intervention":3319,"totalTrials":101,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3332,"activeCount":74},[],{"trials":3334,"activeCount":74},[3335],{"nctId":3313,"briefTitle":3314,"status":80,"phases":3336,"primaryCompletion":812,"completion":812,"start":2526,"enrollment":2692,"conditions":3337,"interventions":3338},[64],[3317],[3306,3319,3320],{"trials":3340,"activeCount":74},[],{"trials":3342,"activeCount":74},[],{"trials":3344,"activeCount":74},[],{"trials":3346,"activeCount":74},[],{"intervention":3320,"totalTrials":101,"cells":3348},{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3357,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3350,"activeCount":74},[],{"trials":3352,"activeCount":74},[3353],{"nctId":3313,"briefTitle":3314,"status":80,"phases":3354,"primaryCompletion":812,"completion":812,"start":2526,"enrollment":2692,"conditions":3355,"interventions":3356},[64],[3317],[3306,3319,3320],{"trials":3358,"activeCount":74},[],{"trials":3360,"activeCount":74},[],{"trials":3362,"activeCount":74},[],{"trials":3364,"activeCount":74},[],{"intervention":3366,"totalTrials":101,"cells":3367},"JNS002",{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3369,"activeCount":74},[],{"trials":3371,"activeCount":74},[3372],{"nctId":3373,"briefTitle":3374,"status":80,"phases":3375,"primaryCompletion":600,"completion":600,"start":1891,"enrollment":35,"conditions":3376,"interventions":3377},"NCT01371227","A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma",[64],[18],[3366],{"trials":3379,"activeCount":74},[],{"trials":3381,"activeCount":74},[],{"trials":3383,"activeCount":74},[],{"trials":3385,"activeCount":74},[],{"intervention":3387,"totalTrials":101,"cells":3388},"ExPEC4V",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3401,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3390,"activeCount":74},[],{"trials":3392,"activeCount":74},[3393],{"nctId":3394,"briefTitle":3395,"status":80,"phases":3396,"primaryCompletion":3397,"completion":3397,"start":3398,"enrollment":2778,"conditions":3399,"interventions":3400},"NCT02748967","A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants",[64],"2016-08","2016-04",[15],[3387],{"trials":3402,"activeCount":74},[],{"trials":3404,"activeCount":74},[],{"trials":3406,"activeCount":74},[],{"trials":3408,"activeCount":74},[],{"intervention":3410,"totalTrials":101,"cells":3411},"JNJ-63733657",{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3413,"activeCount":74},[],{"trials":3415,"activeCount":74},[3416],{"nctId":3417,"briefTitle":3418,"status":80,"phases":3419,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":1743,"conditions":3422,"interventions":3423},"NCT03689153","A Study of JNJ-63733657 in Healthy Japanese Participants",[64],"2019-07-11","2018-09-28",[15],[3410],{"trials":3425,"activeCount":74},[],{"trials":3427,"activeCount":74},[],{"trials":3429,"activeCount":74},[],{"trials":3431,"activeCount":74},[],{"intervention":3433,"totalTrials":101,"cells":3434},"JNJ-67953964",{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3447,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3436,"activeCount":74},[],{"trials":3438,"activeCount":74},[3439],{"nctId":3440,"briefTitle":3441,"status":80,"phases":3442,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":2527,"conditions":3445,"interventions":3446},"NCT04791332","A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants",[64],"2021-07-28","2021-04-30",[15],[3433],{"trials":3448,"activeCount":74},[],{"trials":3450,"activeCount":74},[],{"trials":3452,"activeCount":74},[],{"trials":3454,"activeCount":74},[],{"intervention":3456,"totalTrials":101,"cells":3457},"JNJ-75105186",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3470,"PHASE3":3472,"PHASE4":3474,"NA":3476},{"trials":3459,"activeCount":74},[],{"trials":3461,"activeCount":74},[3462],{"nctId":3463,"briefTitle":3464,"status":2132,"phases":3465,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":74,"conditions":3468,"interventions":3469},"NCT05159128","A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants",[64],"2022-04-02","2021-11-15",[15],[3456],{"trials":3471,"activeCount":74},[],{"trials":3473,"activeCount":74},[],{"trials":3475,"activeCount":74},[],{"trials":3477,"activeCount":74},[],{"intervention":3479,"totalTrials":101,"cells":3480},"JNJ-61393215",{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3493,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3482,"activeCount":74},[],{"trials":3484,"activeCount":74},[3485],{"nctId":3486,"briefTitle":3487,"status":80,"phases":3488,"primaryCompletion":3489,"completion":3489,"start":3490,"enrollment":1743,"conditions":3491,"interventions":3492},"NCT04713930","A Study of JNJ-61393215 in Healthy Japanese Male Participants",[64],"2021-05-31","2021-01-29",[15],[3479],{"trials":3494,"activeCount":74},[],{"trials":3496,"activeCount":74},[],{"trials":3498,"activeCount":74},[],{"trials":3500,"activeCount":74},[],{"intervention":1778,"totalTrials":101,"cells":3502},{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3511,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3504,"activeCount":74},[],{"trials":3506,"activeCount":74},[3507],{"nctId":1770,"briefTitle":1771,"status":80,"phases":3508,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1743,"conditions":3509,"interventions":3510},[64],[15],[1763,1777,1778],{"trials":3512,"activeCount":74},[],{"trials":3514,"activeCount":74},[],{"trials":3516,"activeCount":74},[],{"trials":3518,"activeCount":74},[],{"intervention":3520,"totalTrials":101,"cells":3521},"JNJ-54861911, 10 mg",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3523,"activeCount":74},[],{"trials":3525,"activeCount":74},[3526],{"nctId":3527,"briefTitle":3528,"status":80,"phases":3529,"primaryCompletion":3530,"completion":3530,"start":3531,"enrollment":2692,"conditions":3532,"interventions":3533},"NCT02360657","Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia",[64],"2015-09-08","2015-02-16",[32],[3520,3534],"JNJ-54861911, 50 mg",{"trials":3536,"activeCount":74},[],{"trials":3538,"activeCount":74},[],{"trials":3540,"activeCount":74},[],{"trials":3542,"activeCount":74},[],{"intervention":3534,"totalTrials":101,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3546,"activeCount":74},[],{"trials":3548,"activeCount":74},[3549],{"nctId":3527,"briefTitle":3528,"status":80,"phases":3550,"primaryCompletion":3530,"completion":3530,"start":3531,"enrollment":2692,"conditions":3551,"interventions":3552},[64],[32],[3520,3534],{"trials":3554,"activeCount":74},[],{"trials":3556,"activeCount":74},[],{"trials":3558,"activeCount":74},[],{"trials":3560,"activeCount":74},[],{"intervention":3562,"totalTrials":101,"cells":3563},"RSV Vaccine",{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3576,"PHASE3":3578,"PHASE4":3580,"NA":3582},{"trials":3565,"activeCount":74},[],{"trials":3567,"activeCount":74},[3568],{"nctId":3569,"briefTitle":3570,"status":80,"phases":3571,"primaryCompletion":3572,"completion":3572,"start":3573,"enrollment":84,"conditions":3574,"interventions":3575},"NCT04354480","A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older",[64],"2021-01-20","2020-05-15",[15],[3562],{"trials":3577,"activeCount":74},[],{"trials":3579,"activeCount":74},[],{"trials":3581,"activeCount":74},[],{"trials":3583,"activeCount":74},[],{"intervention":3585,"totalTrials":101,"cells":3586},"JNJ-40411813",{"EARLY_PHASE1":3587,"PHASE1":3589,"PHASE2":3598,"PHASE3":3600,"PHASE4":3602,"NA":3604},{"trials":3588,"activeCount":74},[],{"trials":3590,"activeCount":74},[3591],{"nctId":3592,"briefTitle":3593,"status":80,"phases":3594,"primaryCompletion":3595,"completion":3595,"start":3490,"enrollment":698,"conditions":3596,"interventions":3597},"NCT04677530","A Study of JNJ-40411813 in Healthy Japanese Male Participants",[64],"2021-05-21",[15],[3585],{"trials":3599,"activeCount":74},[],{"trials":3601,"activeCount":74},[],{"trials":3603,"activeCount":74},[],{"trials":3605,"activeCount":74},[],{"intervention":3607,"totalTrials":101,"cells":3608},"JNJ-30979754 15 mg\u002Fm2",{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3627},{"trials":3610,"activeCount":74},[],{"trials":3612,"activeCount":74},[3613],{"nctId":3614,"briefTitle":3615,"status":80,"phases":3616,"primaryCompletion":601,"completion":601,"start":302,"enrollment":698,"conditions":3617,"interventions":3619},"NCT00796003","A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome",[64],[3618],"Myelodysplastic Syndrome",[3607,3620],"JNJ-30979754 20 mg\u002Fm2",{"trials":3622,"activeCount":74},[],{"trials":3624,"activeCount":74},[],{"trials":3626,"activeCount":74},[],{"trials":3628,"activeCount":74},[],{"intervention":3620,"totalTrials":101,"cells":3630},{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3632,"activeCount":74},[],{"trials":3634,"activeCount":74},[3635],{"nctId":3614,"briefTitle":3615,"status":80,"phases":3636,"primaryCompletion":601,"completion":601,"start":302,"enrollment":698,"conditions":3637,"interventions":3638},[64],[3618],[3607,3620],{"trials":3640,"activeCount":74},[],{"trials":3642,"activeCount":74},[],{"trials":3644,"activeCount":74},[],{"trials":3646,"activeCount":74},[],{"intervention":202,"totalTrials":35,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3657,"PHASE3":3659,"PHASE4":3661,"NA":3667},{"trials":3650,"activeCount":74},[],{"trials":3652,"activeCount":74},[3653],{"nctId":2399,"briefTitle":2400,"status":80,"phases":3654,"primaryCompletion":1892,"completion":1892,"start":302,"enrollment":2402,"conditions":3655,"interventions":3656},[64],[18],[2392,2405,2406,2407,202],{"trials":3658,"activeCount":74},[],{"trials":3660,"activeCount":74},[],{"trials":3662,"activeCount":74},[3663],{"nctId":364,"briefTitle":365,"status":80,"phases":3664,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":3665,"interventions":3666},[67],[371],[351,202],{"trials":3668,"activeCount":74},[3669],{"nctId":190,"briefTitle":191,"status":80,"phases":3670,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3671,"interventions":3672},[],[197],[199,200,201,202,203,204,41],{"intervention":1093,"totalTrials":35,"cells":3674},{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3689,"PHASE4":3695,"NA":3697},{"trials":3676,"activeCount":74},[],{"trials":3678,"activeCount":74},[],{"trials":3680,"activeCount":74},[3681],{"nctId":3682,"briefTitle":3683,"status":80,"phases":3684,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":522,"conditions":3687,"interventions":3688},"NCT01945086","A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis",[65],"2014-12","2013-09",[1945],[1093],{"trials":3690,"activeCount":74},[3691],{"nctId":1084,"briefTitle":1085,"status":685,"phases":3692,"primaryCompletion":1087,"completion":1087,"start":1088,"enrollment":1089,"conditions":3693,"interventions":3694},[66],[1091],[1093,1073],{"trials":3696,"activeCount":74},[],{"trials":3698,"activeCount":74},[3699],{"nctId":3700,"briefTitle":3701,"status":80,"phases":3702,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":3705,"conditions":3706,"interventions":3708},"NCT04963725","A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice",[],"2022-12-01","2021-07-18",137,[3707],"Ulcerative Colitis",[1093],{"intervention":199,"totalTrials":101,"cells":3710},{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3712,"activeCount":74},[],{"trials":3714,"activeCount":74},[],{"trials":3716,"activeCount":74},[],{"trials":3718,"activeCount":74},[],{"trials":3720,"activeCount":74},[],{"trials":3722,"activeCount":74},[3723],{"nctId":190,"briefTitle":191,"status":80,"phases":3724,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3725,"interventions":3726},[],[197],[199,200,201,202,203,204,41],{"intervention":200,"totalTrials":101,"cells":3728},{"EARLY_PHASE1":3729,"PHASE1":3731,"PHASE2":3733,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3730,"activeCount":74},[],{"trials":3732,"activeCount":74},[],{"trials":3734,"activeCount":74},[],{"trials":3736,"activeCount":74},[],{"trials":3738,"activeCount":74},[],{"trials":3740,"activeCount":74},[3741],{"nctId":190,"briefTitle":191,"status":80,"phases":3742,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3743,"interventions":3744},[],[197],[199,200,201,202,203,204,41],{"intervention":201,"totalTrials":101,"cells":3746},{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3751,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3748,"activeCount":74},[],{"trials":3750,"activeCount":74},[],{"trials":3752,"activeCount":74},[],{"trials":3754,"activeCount":74},[],{"trials":3756,"activeCount":74},[],{"trials":3758,"activeCount":74},[3759],{"nctId":190,"briefTitle":191,"status":80,"phases":3760,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3761,"interventions":3762},[],[197],[199,200,201,202,203,204,41],{"intervention":203,"totalTrials":101,"cells":3764},{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3766,"activeCount":74},[],{"trials":3768,"activeCount":74},[],{"trials":3770,"activeCount":74},[],{"trials":3772,"activeCount":74},[],{"trials":3774,"activeCount":74},[],{"trials":3776,"activeCount":74},[3777],{"nctId":190,"briefTitle":191,"status":80,"phases":3778,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3779,"interventions":3780},[],[197],[199,200,201,202,203,204,41],{"intervention":204,"totalTrials":101,"cells":3782},{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":74},[],{"trials":3786,"activeCount":74},[],{"trials":3788,"activeCount":74},[],{"trials":3790,"activeCount":74},[],{"trials":3792,"activeCount":74},[],{"trials":3794,"activeCount":74},[3795],{"nctId":190,"briefTitle":191,"status":80,"phases":3796,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":3797,"interventions":3798},[],[197],[199,200,201,202,203,204,41]]